Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 3/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313843 | 0.82 | MAPT (0.48) | MAPTSMN1; SMN2KMT2ARAB9ASCN1A | |
| SCHEMBL18078975 | 0.82 | MAPT (0.56) | MAPTSMN1; SMN2KMT2ARAB9ASCN1A | |
| Hydrochloric Acid SCHEMBL16694536 | 0.81 | ALDH1A1 (0.47) | MAPTSMN1; SMN2KMT2ARAB9AMEN1 | |
| Iodide SCHEMBL30309833 | 0.79 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2KMT2AALDH1A1SSTR4 | |
| SCHEMBL2015133 | 0.78 | SMN1; SMN2 (0.39) | MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1844575 | 0.78 | SCN1A (0.77) | MAPTSMN1; SMN2KMT2ASCN1ASCN2A | |
| SCHEMBL10274500 | 0.77 | HRH3 (0.63) | MAPTSMN1; SMN2KMT2A | |
| SCHEMBL31215478 | 0.77 | SSTR4 (0.60) | MAPTSMN1; SMN2KMT2ARAB9AMEN1 | |
| SCHEMBL1023344 | 0.76 | SCN1A (0.53) | MAPTSMN1; SMN2KMT2ARAB9ASCN1A | |
| Fumaric Acid SCHEMBL11257173 | 0.75 | HRH1 (0.56) | MAPTSMN1; SMN2KMT2AMEN1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621958-B1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-07-10 | — | — | EP | disclosed |
| EP-3268375-B1 | PHOTOCHROMIC THIENOCHROMENE COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3071576-B9 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3071576-B1 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2020-02-13 | — | — | US | disclosed |
| EP-2370420-B9 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-2370420-B1 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2357217-B9 | PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3071550-B1 | METHOD OF PREPARING FUSED RING INDENO COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10005763-B2 | Photochromic compounds | TRANSITIONS OPTICAL, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20080096049-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096049-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096048-A1 | Thermally reversible; absorption ratio greater than 2.3 | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096048-A1 | Thermally reversible; absorption ratio greater than 2.3 | TRANSITIONS OPTICAL, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7342112-B2 | Photochromic compounds | PPG INDUSTRIES OHIO, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342112-B2 | Photochromic compounds | PPG INDUSTRIES OHIO, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-20080051575-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL ,INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051575-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | TRANSITIONS OPTICAL ,INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080045704-A1 | Thermally reversible; absorption ratio greater than 2.3; cell method | TRANSITIONS OPTICAL, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045704-A1 | Thermally reversible; absorption ratio greater than 2.3; cell method | TRANSITIONS OPTICAL, INC. (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | ALDH1A2, RB1, INCENP | MAPT 1822/4885SMN1; SMN2 4769/4885KMT2A 1736/4885 |
| US-20080045704-A1 | Thermally reversible; absorption ratio greater than 2.3; cell method | CCND3, CCND1, CCND2 | MAPT 4145/4885SMN1; SMN2 1316/4885KMT2A 1511/4885 |
| US-20080096048-A1 | Thermally reversible; absorption ratio greater than 2.3 | CCND1, CCND3, CCND2 | MAPT 4150/4885SMN1; SMN2 1502/4885KMT2A 1838/4885 |
| US-10005763-B2 | Photochromic compounds | CCR4, CCR8, CBR3 | MAPT 3402/4885SMN1; SMN2 4001/4885KMT2A 2193/4885 |
| US-20080051575-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | CCND1, CCND2, CCNE1 | MAPT 4085/4885SMN1; SMN2 993/4885KMT2A 1830/4885 |
| US-20080096049-A1 | capable of switching between the two states in response to at least actinic radiation; thermally reversible | CCND1, CCND2, CCNE1 | MAPT 4085/4885SMN1; SMN2 993/4885KMT2A 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.